TNF-α and IFN-α production

TNF-α and IFN-α production refers to the biological synthesis and secretion of Tumor Necrosis Factor-alpha and Interferon-alpha, two essential cytokines that coordinate the body's inflammatory and antiviral responses (Source: PubMed, PMID: 31041315). TNF-α is a major driver of systemic inflammation and is implicated in the pathology of various autoimmune conditions, including rheumatoid arthritis and inflammatory bowel disease (Source: StatPearls, NBK470413). IFN-α, a type I interferon, is critical for host defense against viruses but is also a key driver of the interferon signature observed in systemic lupus erythematosus (Source: Nature Reviews Rheumatology, doi:10.1038/nrrheum.2015.145). This entry represents a physiological process rather than a single molecular target; it is the downstream result of complex signaling networks involving Toll-like receptors (TLRs), IRAK kinases, and the JAK/STAT pathway (Source: UniProt). Therapeutic intervention often targets these upstream components to modulate cytokine levels, as seen with drugs like hydroxychloroquine or selective TLR7/8 inhibitors (Source: Merck KGaA). While reducing the production of these cytokines can be therapeutically beneficial, it also poses significant safety risks, such as increased vulnerability to infections and potential reactivation of latent pathogens (Source: Mayo Clinic). Monitoring these cytokine levels or their downstream gene signatures serves as a vital biomarker for disease activity and treatment efficacy in clinical settings.

Other names

Tumor necrosis factor-alpha and interferon-alpha secretionPro-inflammatory cytokine productionType I interferon and TNF synthesis

The production of these cytokines is modulated by inhibiting upstream signaling proteins such as Toll-like receptors (TLR7, TLR8, TLR9), interleukin-1 receptor-associated kinases (IRAK4), or Janus kinases (JAK1, JAK2), thereby preventing the transcriptional activation and subsequent secretion of TNF-α and IFN-α.